immunotherapy

Australia | Immune Systems | Immunotherapy | International | Mesothelioma | Research | Treatments

Chemoimmunotherapy Called “Next Frontier” for Mesothelioma Cancer
ByAlex Strauss May 5, 2019May 8, 2019

Mesothelioma researchers in Australia are calling the combination of chemotherapy and immunotherapy the “next frontier” in the treatment of mesothelioma cancer. In a study published in the journal Expert Opinions in Biological Therapy, the researchers reviewed past clinical trials on mesothelioma immunotherapy. They focused on studies published between 2016 and 2018. Their goal was to get a clearer picture of just how effective these drugs are and how they might be used in combination with other treatments. Chemotherapy for Mesothelioma Cancer Currently, immunotherapy is not the primary treatment for mesothelioma cancer. Instead, most patients have chemotherapy, which is considered the gold standard treatment. For the past 15 years, Alimta has been the main chemotherapy drug for people with malignant mesothelioma….

Read More Chemoimmunotherapy Called “Next Frontier” for Mesothelioma Cancer
Chemotherapy | Immunotherapy | New Drugs | New Studies | Research | Treatments | Virus

Combination Mesothelioma Therapy Begins Pivotal Trial
ByAlex Strauss April 9, 2019

A combination mesothelioma therapy that showed promise in early trials is finally being studied on a larger scale. The power-packed chemo-immuno-gene therapy known as TR002 has the potential to change the outlook for thousands of malignant mesothelioma patients. A small trial of the combination mesothelioma therapy in 2016 produced “significantly higher” mesothelioma survival rates than most patients are told to expect. Drug company Trizell announced last month that the combination will now be tested on 300 patients at sites in the US, Europe, Australia and Russia. Combination Mesothelioma Therapy Starts with Gene Therapy TR002 is an investigational gene therapy for mesothelioma patients who have failed first-line chemotherapy. This combination mesothelioma therapy is based on the human interferon-alpha 2b gene. The…

Read More Combination Mesothelioma Therapy Begins Pivotal Trial
Europe | Immune Systems | Immunotherapy | International | New Drugs | Research | Treatments

New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy
ByAlex Strauss March 26, 2019April 23, 2019

A Dutch company has recruited the first patients into a pivotal mesothelioma clinical trial of autologous dendritic cells. Dendritic cells are immune system cells that work as messengers. They help tell T cells to attack cancers like malignant mesothelioma. The new mesothelioma clinical trial will test using the patient’s own dendritic cells (autologous cells) as a way to keep cancer from coming back after mesothelioma treatment. Expanding Mesothelioma Treatment Options There is only one approved treatment for malignant pleural mesothelioma. This “standard of care” treatment is chemotherapy with Alimta (pemetrexed) and cisplatin. Although most mesothelioma patients receive this treatment, very few live longer than a year after diagnosis. A Netherlands-based company called Amphera is trying to change those odds. Its…

Read More New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy
Europe | Immune Systems | Immunotherapy | International | New Drugs | Research | Treatments

PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma
ByAlex Strauss March 12, 2019

A new study suggests that drugs known as PARP inhibitors may enhance immunotherapy response in mesothelioma patients. According to a report published in the Journal of Clinical Investigations, PARP inhibitors worked especially well in cancers with mutations in their DNA repair genes. Some malignant mesothelioma patients have mutated DNA repair genes. In these patients, a PARP inhibitor may modify immunotherapy response, making drugs like Keytruda work better. How PARP Impacts Immunotherapy Response PARP stands for poly (ADP-ribose) polymerase. It represents a family of proteins involved in a number of cellular processes, including DNA repair. PARP is also involved in apoptosis, or programmed cell death. Olaparib (Lynparza) is an example of a PARP inhibitor. PARP inhibitors attack tumors that already have…

Read More PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma
Europe | International | New Studies | Research | Symptoms | Treatments

Predicting Thyroid Disease After Immunotherapy for Mesothelioma
ByAlex Strauss March 7, 2019

Researchers in Italy say it is possible to predict which mesothelioma patients are likely to develop thyroid disease after immunotherapy. They are advising their colleagues to use the technique for better management of malignant mesothelioma. Immune checkpoint inhibitors like Keytruda are improving the outlook for people with asbestos cancer. But immunotherapy is not without risk. Certain people are prone to develop thyroid disease after immunotherapy. If doctors know ahead of time which mesothelioma patients are at risk, they can be better prepared to manage problems later. Immune Checkpoint Inhibitors and Thyroid Disease after Immunotherapy Pleural mesothelioma is extremely difficult to treat. Immune checkpoint inhibitors have given many mesothelioma patients new hope. Recent studies suggest that some of these drugs…

Read More Predicting Thyroid Disease After Immunotherapy for Mesothelioma
Immune Systems | Immunotherapy | Research | Treatments

Mesothelioma Research Demonstrates Power of Intrapleural Immunotherapy
ByAlex Strauss March 2, 2019March 2, 2019

New metadata suggests that intrapleural immunotherapy is a powerful, targeted way to treat malignant pleural mesothelioma. Pleural mesothelioma is a deadly cancer of the lining around the lungs. It is caused by asbestos exposure and is notoriously difficult to treat. Now, a new study suggests that delivering immunotherapy treatments directly into the pleural space where mesothelioma tumors form may help these drugs work even better. What is Intrapleural Immunotherapy? Immunotherapy treatments harness the immune system to help fight cancer. Immunotherapy works alone or in combination with other treatments like chemotherapy or surgery. Many researchers and doctors believe that immunotherapy is the future of mesothelioma treatment. Intrapleural immunotherapy is a more targeted way to deliver these cancer-fighting messengers. It does…

Read More Mesothelioma Research Demonstrates Power of Intrapleural Immunotherapy
Asia | Immune Systems | Immunotherapy | International | Research | Treatments | Updates

New Mesothelioma Immunotherapy Treatment Reduces Tregs with Immunotoxin
ByAlex Strauss February 17, 2019

There is a new mesothelioma immunotherapy treatment in the works. This one is based on reducing the number of Tregs or regulatory T-cells around a mesothelioma tumor. Tregs are an important part of maintaining balance in the immune system. They help protect people against autoimmune diseases like MS and lupus. But in people with malignant mesothelioma and other types of cancer, too many Tregs can be a problem. Tregs respond to distress signals sent out by a tumor. They surround the tumor and protect it against attack from the immune system. The goal of mesothelioma immunotherapy treatment is to reactivate the immune system to fight the cancer. Developing a Mesothelioma Immunotherapy Treatment Molecular biologists at the National Cancer Institute and…

Read More New Mesothelioma Immunotherapy Treatment Reduces Tregs with Immunotoxin
Immunotherapy | New Studies | Research | Treatments

Avelumab May Offer a Second-Line Option for Recurrent Mesothelioma
ByAlex Strauss January 8, 2019

People with recurrent mesothelioma may get another chance at treatment with the immunotherapy drug avelumab. Malignant mesothelioma is highly resistant to standard cancer therapies. That means that the asbestos cancer usually comes back, or recurs, even after treatment. The most common treatment for mesothelioma is chemotherapy with Alimta. Alimta is the only drug approved specifically for mesothelioma. Patients with recurrent mesothelioma often have several rounds of chemotherapy with Alimta. But once the standard mesothelioma treatments stop working, patients do not have many options. Now a new study suggests that some cases of recurrent mesothelioma that stop responding to Alimta may respond to avelumab. Considering Avelumab for Recurrent Mesothelioma Bavencio is the brand name for avelumab. It is a type…

Read More Avelumab May Offer a Second-Line Option for Recurrent Mesothelioma
Asia | Immunotherapy | International | Research | Treatments | Virus

Virotherapy for Mesothelioma Can Be More Effective
ByAlex Strauss December 15, 2018

Hong Kong researchers may have found a way to get around one of the biggest challenges of virotherapy for mesothelioma. Virotherapy uses a modified virus to deliver medicine or genetic information into the body. Modified viruses are useful because they can be “programmed” to seek out cancer cells. But modified viruses do not always behave the way scientists hope they will. One problem with some virotherapy for mesothelioma is that it can block the natural immune response. The body naturally fights malignant mesothelioma by releasing white blood cells called CTLs (T lymphocytes). But MVTT virotherapy can prevent the release of CTLs, even while it attacks the tumor. “Although MVTT [a type of virotherapy] leads to regression of established mesothelioma dose-dependently,…

Read More Virotherapy for Mesothelioma Can Be More Effective
Immune Systems | New Drugs | New Studies | Research | Surgery | Treatments

Survival After Mesothelioma Surgery Could Rise with Immunotherapy Spray
ByAlex Strauss December 10, 2018

A spray-on immune booster may one day improve survival after mesothelioma surgery. UCLA scientists tested the biodegradable spray gel in mice with advanced melanoma. They found that it stopped cancer recurrence after surgery in about half of the lab animals tested. “Around 90 percent of people with cancerous tumors end up dying because of tumor recurrence or metastasis,” says lead investigator Zhen Gu. “Being able to develop something that helps lower this risk for this to occur and has low toxicity is especially gratifying.” Gu is a professor of bioengineering and a member of the UCLA Jonsson Comprehensive Cancer Center where the spray was developed. Survival After Mesothelioma Surgery Survival after mesothelioma surgery or any other kind of cancer operation…

Read More Survival After Mesothelioma Surgery Could Rise with Immunotherapy Spray

Get your free copy of

“Surviving Mesothelioma” Today

Get Your Free Copy »